期刊
JOURNAL OF THE NEUROLOGICAL SCIENCES
卷 383, 期 -, 页码 31-34出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2017.10.015
关键词
No evident disease activity; Multiple sclerosis; Disease modifying therapy; Outcome measures; Treatment target
资金
- Sanofi
- Novartis
- Biogen Pharmaceuticals
- National Multiple Sclerosis Foundation
- Alexion
- TerumoBCT
No evident disease activity (NEDA) is a proposed measure of disease activity-free status in multiple sclerosis (MS) that is typically defined as absence of relapses, disability progression, and MRI activity over a defined time period. NEDA is increasingly reported in randomized controlled trials of MS disease modifying therapies where it has some perceived advantages over outcomes such as annualized relapse rate. NEDA has also been proposed as a treatment goal in clinical care. At this point, the long-term implications of early NEDA remain largely unknown. We review current NEDA definitions, use in clinical trials, and its prospects for routine use as an actionable treatment target in clinical practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据